The “off-label” promotion and marketing of drugs by the pharmaceutical industry is a huge driver of profits. Take Cordarone® for instance. Wyeth’s campaign to promote this drug for the treatment of Atrial fibrillation was so successful that Wyeth made an estimated $3 billion from this “off-label” use.
Amiodarone is the only drug in modern FDA history, to be approved for use in the United States without undergoing any of the required randomized, clinical studies to show a drug is safe and effective before it is approved.
On January 3, 2018, after The Register broke the news of massive security vulnerabilities in all of Intel’s CPUs since 2004, Doyle APC filed the first class action complaint against Intel Corporation for damages caused by these security defects.